




1. PRODUCT AND COMPANY INFORMATION

Distributed By: WG Critical Care, LLC.
120 Route 17 North
Suite 115
Paramus, NJ 07652 USA

Product Name: **CISPLATIN INJECTION**

Active Ingredient Primary Component: Cisplatin

Structure:



Chemical Name: (1) Platinum, diamminedichloro-, (SP-4-2)-; (2) *cis*-Diamminedichloroplatinum.

Molecular Formula: $Cl_2H_6N_2Pt$

UNII Code: UNII-Q20Q21Q62J

CAS Number: 15663-27-1

Chemical Family: Antineoplastic

Product Use: Pharmaceutical

Product Type: Prescription Drug

Container Information: Multi Dose Vials

Customer Service Phone Number: +1-888-493-0861

Emergency Phone Number: +1-866-562-4708 (Prosar)

WG Critical Care, LLC.

Cisplatin Injection	Safety Data Sheet (SDS)		
Version: 2.3	Issue Date: July 16, 2015		Page 1 of 6



2. HAZARDS IDENTIFICATION

PRIMARY PHYSICAL AND HEALTH HAZARDS: Potential hazards and adverse reactions are described in the package insert.

ROUTES OF ENTRY: Inhalation, ingestion, eye contact, skin contact, injection

SIGNS & SYMPTOMS OF EXPOSURE: Adverse events from therapeutic doses include: nephrotoxicity, neuropathies, myelosuppression, fever, infection, nausea, vomiting, ototoxicity, tinnitus, hearing loss, deafness, and vestibular toxicity. Anaphylactic like reactions of facial edema, bronchoconstriction, tachycardia, and hypotension have also been reported. Occupational exposure has not been fully investigated.

CHEMICAL LISTED AS CARCINOGEN: **NTP:** NO **IARC:** NO **OSHA:** NO

3. COMPOSITION / INFORMATION ON INGREDIENTS

<u>Ingredient</u>	<u>Weight %</u>	<u>CAS No.</u>
Cisplatin		15663-27-1

4. FIRST AID MEASURES

EYE EXPOSURE: May cause eye irritation

SKIN EXPOSURE: May cause skin irritation

INGESTION: Harmful if swallowed. Gastrointestinal effects (may include nausea, upset stomach, loss of appetite). Renal function effects (may include increased levels of creatinine, BUN, renal failure). Blood effects (may include anemia, neutropenia (decreased number of neutrophils), thrombocytopenia (decreased number of platelets), bone marrow depression). Liver function effects (may include increased levels of SGOT, SGPT, serum LDH, jaundice). Ocular toxicity effects. Electrolyte imbalance. May cause hearing loss.

INHALATION: Not likely under normal use conditions

NOTE TO PHYSICIAN: See patient package insert in shipping carton for complete information

WG Critical Care, LLC.

Cisplatin Injection		Safety Data Sheet (SDS)	
Version: 2.3	Issue Date: July 16, 2015		Page 2 of 6



5. FIRE FIGHTING MEASURES

FLASH POINT:	Not established
AUTO-IGNITION TEMPERATURE:	Not established
FLAMMABLE LIMITS IN AIR:	Not established
FLAMMABLE LIMITS:	Not established
EXTINGUISHING MEDIA:	Use foam or an all purpose dry chemical to extinguish
UNUSUAL FIRE / EXPLOSION HAZARDS:	Not known

6. ACCIDENTAL RELEASE MEASURE

SPILL: Methods for Cleaning:	If emergency personnel are unavailable, contain spilled material. For small spills add absorbent (soil may be used in the absence of other suitable materials) scoop up material and place in a sealed, liquid-proof container for disposal. For large spills dike spilled material or otherwise contain material to ensure runoff does not reach a waterway. Place spilled material in an appropriate container for disposal
RELEASE TO WATER:	Do not allow release to water

7. HANDLING AND STORAGE

GENERAL HANDLING:	Do not ingest. Wash thoroughly after handling
STORAGE CONDITIONS:	Keep containers tightly closed in a cool well ventilated place. Store between 15-25 ⁰ C. Do not refrigerate. Protect from Light

WG Critical Care, LLC.

Cisplatin Injection	Safety Data Sheet (SDS)		
Version: 2.3	Issue Date: July 16, 2015		Page 3 of 6



8. EXPOSURE CONTROLS / PERSONAL PROTECTION

RESPIRATORY PROTECTION: No personal respiratory protective equipment is normally required

EYE PROTECTION: Eye protection is only required (safety glasses w/ side shields) during laboratory and manufacturing. Not required for normal final product use.

VENTILATION Open handling must be limited. Provide general and/or local exhaust ventilation

SKIN PROTECTION: Work uniform and/or laboratory coat. Additional garments should be based on task being performed. Disposable outer garments should be used when there is a potential for contact with the material

9. PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE:	Liquid	SPECIFIC GRAVITY:	Not Available
APPEARANCE AND ODOR:	Aqueous Liquid	EVAPORATION RATE:	Not Available
BOILING POINT:	Not Available	MELTING POINT:	Not Available
VAPOR PRESSURE:	Not Available	SOLUBILITY IN WATER:	Soluble
VAPOR DENSITY:	Not Available	pH:	3.8-5.9

10. STABILITY AND REACTIVITY

STABILITY: Stable under recommended storage conditions

INCOMPATIBILITY : (MATERIALS TO AVOID) Aluminum

HAZARDOUS POLYMERIZATION: Not Applicable

HAZARDOUS DECOMPOSITION: Not Established

CONDITIONS TO AVOID: Not Established

WG Critical Care, LLC.

Cisplatin Injection		Safety Data Sheet (SDS)	
Version: 2.3	Issue Date: July 16, 2015		Page 4 of 6



11. TOXICOLOGICAL INFORMATION

ACUTE TOXICITY

COMPONENT	TYPE	ROUTE	SPECIES	DOSAGE
Cisplatin	LD ₅₀	Oral	Rat	25.58mg/kg

Acute Toxicity: Gastrointestinal effects (may include nausea, upset stomach, loss of appetite). Renal function effects (may include increased levels of creatinine, BUN, renal failure). Blood effects (may include anemia, neutropenia (decreased number of neutrophils), thrombocytopenia (decreased number of platelets), bone marrow depression). Liver function effects (may include increased levels of SGOT, SGPT, serum LDH, jaundice). Electrolyte imbalance. Ocular toxicity effects. May cause hearing loss. May cause allergic reactions.

Chronic Toxicity: Target Organs: Ear. Blood. Kidney. Bone marrow. Nervous system. Skin. Gastrointestinal tract.

Carcinogenic Effects: Listed by IARC, NTP. Reasonably anticipated to be a human carcinogen

Mutagenic Effects: Considered Mutagenic

Reproductive Toxicity: Can impair fertility. Considered fetotoxic.

FDA Pregnancy Category: D

12. ECOLOGICAL INFORMATION

None Established.

13. DISPOSAL CONSIDERATIONS

Recommend disposal as a hazardous waste

WASTE DISPOSAL: Waste disposal must be in accordance with appropriate Federal, State, and local regulations

14. TRANSPORT INFORMATION

REGULATORY ORGANIZATIONS:

DOT: Not Regulated

ICAO / IATA: Not Regulated

IMO: Not Regulated

WG Critical Care, LLC.

Cisplatin Injection	Safety Data Sheet (SDS)		
Version: 2.3	Issue Date: July 16, 2015		Page 5 of 6



15. REGULATORY INFORMATION

Below is selected regulatory information chosen primarily for possible WG Critical Care use. This section is not a complete analysis or reference to all applicable regulatory information. Please consider all applicable laws and regulations for your city / state / country.

US Regulations

TSCA – No

CERCLA-No

SARA 302 – No

SARA 313 – No

OSHA Substance Specific - No

16. OTHER INFORMATION

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

WG Critical Care, LLC.

Cisplatin Injection	Safety Data Sheet (SDS)		
Version: 2.3	Issue Date: July 16, 2015		Page 6 of 6